MA53817A - Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv - Google Patents

Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv

Info

Publication number
MA53817A
MA53817A MA053817A MA53817A MA53817A MA 53817 A MA53817 A MA 53817A MA 053817 A MA053817 A MA 053817A MA 53817 A MA53817 A MA 53817A MA 53817 A MA53817 A MA 53817A
Authority
MA
Morocco
Prior art keywords
biphenyl
treatment
type
sulfonamide compounds
collagen diseases
Prior art date
Application number
MA053817A
Other languages
English (en)
Inventor
Celia Jenkinson
Radko Komers
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of MA53817A publication Critical patent/MA53817A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA053817A 2018-10-04 2019-10-03 Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv MA53817A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30

Publications (1)

Publication Number Publication Date
MA53817A true MA53817A (fr) 2021-08-11

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053817A MA53817A (fr) 2018-10-04 2019-10-03 Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv

Country Status (12)

Country Link
US (1) US11207299B2 (fr)
EP (1) EP3860594A1 (fr)
JP (1) JP2022514152A (fr)
KR (1) KR20210081338A (fr)
CN (1) CN113286587A (fr)
AU (1) AU2019354784A1 (fr)
BR (1) BR112021006132A2 (fr)
CA (1) CA3114434A1 (fr)
IL (1) IL281965A (fr)
MA (1) MA53817A (fr)
MX (1) MX2021003606A (fr)
WO (1) WO2020072814A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049764A (zh) 2016-10-13 2019-07-23 雷特罗芬公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
WO2022246200A1 (fr) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Méthodes de traitement de maladies ou de troubles rénaux
WO2022266370A1 (fr) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan pour le traitement de la fibrose pulmonaire idiopathique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AU2092601A (en) 1999-12-15 2001-06-25 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP2012522058A (ja) 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤
WO2010135350A2 (fr) 2009-05-20 2010-11-25 Pharmacopeia, Llc Composes intermediaires de biphenyle et procedes pour la preparation d'un double antagoniste de recepteur d'angiotensine ii et d'endotheline
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
CN110049764A (zh) * 2016-10-13 2019-07-23 雷特罗芬公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
WO2020132594A1 (fr) 2018-12-21 2020-06-25 Retrophin, Inc. Compositions de sparsentan amorphe

Also Published As

Publication number Publication date
IL281965A (en) 2021-05-31
AU2019354784A1 (en) 2021-04-15
KR20210081338A (ko) 2021-07-01
MX2021003606A (es) 2021-08-16
US20200147050A1 (en) 2020-05-14
CN113286587A (zh) 2021-08-20
WO2020072814A1 (fr) 2020-04-09
JP2022514152A (ja) 2022-02-10
BR112021006132A2 (pt) 2021-07-20
CA3114434A1 (fr) 2020-04-09
EP3860594A1 (fr) 2021-08-11
US11207299B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA52003A (fr) Procédés de traitement de maladies associées au hpv
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
MA41841A (fr) Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA51524A (fr) Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
MA53817A (fr) Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv
IL276383B1 (en) Treatment of ophthalmological diseases
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA53127A (fr) Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
MA47820A (fr) Traitement de la glycogénose de type iii
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA51738A (fr) Composés pour le traitement de la douleur
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies
MA42930A (fr) Traitement de maladies neurodégénératives
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial